INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freeport-McMoran Inc. - FCX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Freeport and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Freeport issued a press release announcing the suspension of mining activities at its Grasberg Block Cave operation in Indonesia, after “a large flow of wet material from a production drawpoint . . . blocked access to certain areas within the mine,” trapping seven workers. 

On this news, Freeport’s stock price fell $2.80 per share, or 5.99%, to close at $43.87 per share on September 9, 2025. 

Then, on September 24, 2025, Freeport provided an update on the incident, reporting that two of the seven workers were “fatally injured” and that the remaining five workers “remain missing.” 

On this news, Freeport’s stock price fell $7.69 per share, or 16.95%, to close at $37.67 per share on September 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  MoonLake Immunotherapeutics (“Moonlake” or the “Company”) (NASDAQ: MLTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Moonlake and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 28, 2025, MoonLake reported disappointing results from its Phase 3 VELA trials evaluating the efficacy and safety of sonelokimab.  One trial failed to meet its primary endpoint, while the other showed only modest gains versus placebo. 

Following this news, MoonLake’s stock price fell $55.75 per share, or 89.93%, to close at $6.24 per share on September 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brunello Cucinelli S.p.A. - BCUCY

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or the “Company”) (OTCMKTS: BCUCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Brunello Cucinelli and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 25, 2025, Morpheus Research published a report entitled “From Moscow to TJ Maxx - How Brunello Cucinelli Continues To Lie About Its Russian Business While Aggressive Discounting Damages Its Exclusive Positioning.”  The report alleges that, contrary to its own representations, Brunello Cucinelli has continued to unlawfully conduct business in Russia following its invasion of Ukraine. 

On this news, Brunello Cucinelli’s American Depositary Receipt (“ADR”) price fell $2.01 per ADR, or 16.54%, to close at $10.14 per ADR on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Firefly Aerospace Inc. - FLY

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Firefly Aerospace Inc. (“Firefly” or the “Company”) (NASDAQ: FLY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Firefly and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On or around August 7, 2025, Firefly conducted an initial public offering of 19.3 million shares of common stock priced at $45.00 per share.  Then, on September 23, 2025, Firefly reported its financial results for the second quarter of 2025.  Among other items, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to $58.7 million, or $4.60 per share, for the same quarter last year.  Firefly also reported revenue of $15.55 million, below analyst estimates of $17.25 million and down 26.2% from the same quarter last year. 

On this news, Firefly’s stock price fell $7.58 per share, or 15.31%, to close at $41.94 per share on September 23, 2025. 

Then, on September 29, 2025, Firefly disclosed that “[d]uring testing at Firefly's facility in Briggs, Texas, the first stage of Firefly’s Alpha Flight 7 rocket experienced an event that resulted in a loss of the stage.” 

On this news, Firefly’s stock price fell $7.66 per share, or 20.73%, to close at $29.30 per share on September 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Informatica Inc. - INFA

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Informatica Inc. (“Informatica” or the “Company”) (NYSE: INFA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Informatica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

We are investigating Informatica Inc. (INFA) (“Informatica” or the “Company”) for potential violations of the federal securities laws.  On February 13, 2025, Informatica reported its fourth quarter of 2024 and fiscal 2024 financial results, missing financial projections.  Specifically, Informatica reported a 3.8% year-over-year decrease in GAAP total revenues, a 2% year-over-year decrease in GAAP subscription revenues, and a 3.9% year-over-year decrease at the midpoint of the range in non-GAAP operating income. 

On this news, Informatica’s stock price fell $5.42, or 21.53%, to close at $19.75 per share on February 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Organogenesis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On September 25, 2025, Organogenesis issued a press release disclosing that a second phase 3 trial of its cryopreserved amniotic suspension allograft ReNu missed its primary endpoint, having failed to achieve a significantly significant change in pain reduction.  The Company said it would ask for a pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration by the end of October to examine a submission pathway, “including using the combined efficacy analysis from both Phase 3 studies to support a BLA approval,” according to Chief Operating Officer Patrick Bilbo.

On this news, Organogenesis’s stock price fell $0.58 per share, or 12.39%, to close at $4.10 per share on September 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolve AI PLC - RZLV

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Rezolve AI PLC (“Rezolve” or the “Company”) (NASDAQ: RZLV).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Rezolve and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, Fuzzy Panda Research published a report entitled “Rezolve AI (RXLV): Faking ARR by Acquiring Failing AI Start-ups w/ Declining Revenue; Promotional CEO’s History of False Statements”.  The Fuzzy Panda report alleged, among other things, that although Rezolve “tout[ed] itself as an AI company[,]” it “was really still a mobile phone related tech company” and was “misrepresenting its artificial intelligence capabilities and revenue growth.”

On this news, Rezolve’s stock price fell $0.97 per share, or 16.3%, over the following two trading sessions, to close at $4.98 per share on September 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Larimar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, Larimar issued a press release announcing data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.  Although Larimar characterized the data as “positive”, the press release disclosed that anaphylaxis or a severe allergic reaction was reported in seven participants. 

On this news, Larimar’s stock price fell $1.72 per share, or 33.66%, to close at $3.38 per share on September 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 18, 2025, Hunterbrook Media (“Hunterbrook”) published a short report entitled “Dexcom’s Fatal Flaws”.  The Hunterbrook report alleged, among other things, that Dexcom “made an unauthorized design change to a key component of the G7”, the Company’s continuous glucose monitoring system for diabetes management, and that “G7 users have been hospitalized and died” following inaccurate glucose readings from G7 devices. 

On this news, Dexcom’s stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediaAlpha, Inc. - MAX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  MediaAlpha, Inc. (“MediaAlpha” or the “Company”) (NYSE: MAX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 24, 2024, Wolfpack Research published a report entitled “MAX: Our Investigation Reveals MAX Is Participating in Consumer Fraud.”  In pertinent part, Wolfpack announced that it was “short the insurance lead generator, MediaAlpha, Inc. (NYSE: MAX) following our research into the company’s [Health Insurance] segment[.]”  Wolfpack stated that it believed “[MediaAlpha] uses dishonest and sometimes outright fraudulent ads along with deceptive websites to trick consumers into providing their personal information in exchange for a health insurance ‘quote.’  [MediaAlpha] then sells this information as raw lead data or uses it to generate clicks or calls for its lead-buying partners.  Our investigation indicates as much as 78% of [MediaAlpha’s] Health [Insurance] lead-buying partners are running boiler room health insurance scams or are flagrantly violating laws concerning telemarketing.” 

On this news, MediaAlpha’s stock price fell $1.92 per share, or 11.84%, over the following two trading sessions, to close at $14.29 per share on June 25, 2024. 

Then, on November 4, 2024, MediaAlpha disclosed receipt of a letter from the Federal Trade Commission (“FTC”) staff stating that the FTC staff was “prepared to recommend the filing of a complaint against the Company,” claiming that MediaAlpha falsely “represented itself as affiliated with government entities, made misleading claims (in particular regarding health insurance products and use of consumers' personal information) and utilized deceptive advertising.” 

On this news, MediaAlpha’s stock price fell $4.46 per share, of 27.7%, to close at $11.62 per share on November 5, 2024. 

Then, on August 6, 2025, MediaAlpha announced it was settling claims with the FTC for $45 million.  According to the FTC’s complaint, MediaAlpha would use advertisements and websites claiming to provide health insurance quotes to collect information from consumers looking for insurance, while in reality, MediaAlpha sold nothing to consumers, and the consumer information it collected would be sold to telemarketers.  According to the FTC, MediaAlpha sold approximately 119 million leads about consumers in 2024 alone.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celanese Corporation - CE

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Celanese Corporation (“Celanese” or the “Company”) (NYSE: CE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Celanese and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 4, 2024, Celanese issued a press release reporting its financial results for the third quarter of 2024.  Celanese’s reported earnings adjusted for one-time items in the third quarter were $2.44 per share, compared with a consensus estimate of $2.84 per share.  Celanese also reported revenue of $2.65 billion, representing a 2.6% year-over-year decline and falling short of consensus estimates of $2.69 billion.  In the press release, Celanese’s Chief Executive Officer stated that “[i]n the third quarter, we faced a severely constrained demand environment that, in some cases like auto, degraded swiftly” and cautioned investors that “[w]e expect demand conditions to worsen in the fourth quarter, as automotive and industrial segments react to recent dynamics by seasonally destocking at heavier than normal levels.” 

On this news, Celanese’s stock price fell $32.50 per share, or 26.32%, to close at $91.00 per share on November 5, 2024. 

Then, on February 18, 2025, Celanese issued a press release reporting its financial results for the fourth quarter and full year 2024.  Among other items, Celanese “reported full year 2024 U.S. GAAP diluted loss per share of $13.86 and adjusted earnings per share of $8.37”, as well as “net sales of $10.3 billion in 2024, a 6 percent decrease from the previous year consisting of a 4 percent decline in price and a 1 percent decline in volume, with a small currency impact.”  Celanese attributed its results to “[p]ersistently weak global demand in critical end-markets like automotive, paints, coatings, construction and industrial[.]” 

On this news, Celanese’s stock price fell $15.00 per share, or 21.46%, to close at $54.91 per share on February 19, 2025. 

Then, on August 11, 2025, Celanese reported disappointing financial results for yet another quarter.  Among other items, Celanese said that volumes in its Engineered Materials segment were still below normal levels due to easing of destocking in Europe. 

On this news, Celanese’s stock price fell another $6.20 per share, or 13.07%, to close at $41.22 per share on August 12, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Hain Celestial Group, Inc. - HAIN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  The Hain Celestial Group, Inc. (“Hain” or the “Company”) (NASDAQ: HAIN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Hain and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 15, 2025, Hain issued a press release reporting its financial results for the fourth quarter and fiscal year 2025.  Acknowledging Hain’s disappointing results, the Company’s interim Chief Executive Officer said that “[w]e are taking decisive action to optimize cash, deleverage our balance sheet, stabilize sales, and improve profitability as we recognize our performance has not met expectations[.]” 

On this news, Hain’s stock price fell $0.53 per share, or 24.65%, to close at $1.62 per share on September 15, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Matrix Service Company - MTRX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Matrix Service Company (“Matrix” or the “Company”) (NASDAQ: MTRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Matrix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Matrix issued a press release announcing its fiscal year 2025 fourth quarter and full-year results.  For the quarter, Matrix reported non-GAAP earnings per share of -$0.28, missing consensus estimates by $0.29, and revenue of $216.4 million, missing consensus estimates by $15.85 million.  Matrix stated that “[o]ur fourth quarter net income reflects a $14.9 million impact associated with four issues: a charge related to labor cost overruns on a crude oil terminal project, which is now complete; an updated reserve to a contract dispute on a project dating back to the pandemic, currently in arbitration; a charge for an unfavorable court decision related to a subcontractor’s failure to pay lower tier contractors for another pandemic era project; and restructuring costs related to our organizational realignment.” 

On this news, Matrix’s stock price fell $1.98 per share, or 13.89%, to close at $12.27 per share on September 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galiano Gold Inc. - GAU

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Galiano Gold Inc. (“Galiano” or the “Company”) (NYSE: GAU).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Galiano and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Galiano issued a press release describing “an incident that occurred at its Asanko Gold Mine” in Ghana, which “involved a confrontation between community members and military personnel on the Company’s operating concessions[.]”  Galiano stated that “[t]ensions escalated within the local community, leading to civil unrest, including a fatality and damage to contractor equipment.” 

On this news, Galiano’s stock price fell $0.18 per share, or 7.03%, to close at $2.38 per share on September 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lesaka Technologies, Inc. - LSAK

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Lesaka Technologies, Inc. (“Lesaka” or the “Company”) (NASDAQ: LSAK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Lesaka and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 10, 2025, Lesaka disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”) that the Audit Committee of its Board of Directors had “concluded that the Company’s unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively, included in the Company’s Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively (the “Quarterly Reports”), should be restated, and that such unaudited condensed financial statements should no longer be relied upon, due to the Company’s re-evaluation of the classification of certain revenue that has been reported as an agent rather than as principal, and related cost of goods sold.” 

On this news, Lesaka’s stock price fell $0.48 per share, or 10.15%, to close at $4.25 per share on September 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synopsys, Inc. - SNPS

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Synopsys and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Synopsys issued a press release reporting its financial results for the third quarter of its 2025 fiscal year.  In the press release, Synopsys’s Chief Executive Officer stated that “our IP business underperformed expectations” and said that the Company was “taking a more conservative view of Q4, while guiding another year of profitable growth.”  Following these announcements, Baird downgraded Synopsys’s rating to Neutral from Outperfrom and lowered its price target to $535 from $670.

On this news, Synopsys’s stock price fell $216.59 per share, or 35.84%, to close at $387.78 per share on September 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PACS Group, Inc. - PACS

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  PACS Group, Inc. (“PACS” or the “Company”) (NYSE: PACS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether PACS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2025, PACS announced the resignation of Derick Apt “from his role as Chief Financial Officer” after “the Audit Committee of the Company’s board of directors became aware of allegations that Mr. Apt had accepted a series of high-value items from individuals associated with a group of related entities with which the Company does business” and subsequently found “that Mr. Apt’s receipt of these items of value violated company policies, including the Company’s Code of Conduct.” 

On this news, PACS’s stock price fell $3.29 per share, or 29.08%, to close at $8.03 per share on September 9, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Avita and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 7, 2025, Avita reported its financial results for the second quarter of 2025.  Among other items, Avita disclosed “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.”  Avita explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of Recell “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.”  Accordingly, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures.  This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.” 

On this news, Avita’s stock price fell $1.13 per share, or 21%, to close at $4.25 per share on August 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 30, 2025, Summit issued a press release “announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]”  Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause. 

On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. 

Then, on September 7, 2025, Summit announced additional data from the trial, in which ivonescimab produced weaker results in patients from North America and Europe than in those from Europe. 

On this news, Summit’s stock price fell $6.54 per share, or 25.15%, to close at $19.45 per share on September 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Agios and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 4, 2025, Agios issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.”  

On news of the delayed review, Agios’s stock price fell $4.48 per share, or 11.03%, to close at $36.13 per share on September 4, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.